Halozyme Therapeutics Inc. HALO
Super Investor & Insider
1
Fondi che lo detengono
#1487
Rank consenso
1.4%
% dei portafogli
$261,687
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Richard Pzena · Pzena Investment Management | 0% | Reduce 5.35% | 4,049 | $261,687 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monocl…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees423
TickerHALO
Statistics
Market Cap$8.16B
Revenue (TTM)$1.40B
Net Income$316.9M
Net Margin22.7%
EPS$2.56
P/E24.82
P/S5.56
P/B38.17
EV/EBITDA10.72
ROE99.4%
Dividend Yield—
Price$68.85
Data: Twelve Data · Revenue = mcap / P/S